PepPool: CEF (CD8), human 3616-1 from Mabtech AB

Product Specs
ItemPepPool: CEF (CD8), human
CompanyMabtech AB
Price $140.00Supplier Page View Company Product Page
Catalog Number3616-1
SizeOne vial
ApplicationsT cell stimulation,ELISpot,FluoroSpot,Flow cytometry
Reactivityhuman
ComponentsCEF peptide pool (lyophilized)

Add to Compare List

Mabtech AB

Box 1233

Nacka Strand, SE-131 28

Sweden

Phone: +46 8 716 27 00
+46 8 716 27 01

Company Profile

Website: http://www.mabtech.com

(1) Stereotactic ablative radiotherapy-driven immunosuppression is associated with poorer progression-free survival in cancer patientsCancer Immunol ImmunotherDecember 18, 2025Jessica Oliver, Hannah Reed, Lorenzo Capitani, Ashley Poon-King, Ashleigh Young, Stefan Milutinovic, Mateusz Kuczynski, Owen Nicholas, Thomas Rackley, Catherine Pembroke, et al.individuals are able to mount a measurable response against them [30]. The CEF peptide pool (Mabtech, Cat#3616-1) which contains 23 HLA-I restricted epitopes from Cytomegalovirus, Epstein–Barr virus, and influenza virus

(2) Early de novo T cell expansion following SARS-CoV-2 infection predicts favourable clinical and virological outcomesEBioMedicineJune 4, 2025Joe Fenn, Aleksandra Koycheva, Rhia Kundu, Mica Tolosa-Wright, Lulu Wang, Janakan Sam Narean, Emily Conibear, Seran Hakki, Jakob Jonnerby, Samuel Baldwin, et al.Germany). Anti-CD3 and anti-CD28 (100 ng/ml) (FSP-0102-10, Mabtech, Stockholm, Sweden), and CEF (1 μg/ml) (3616-1, Mabtech, Stockholm, Sweden) were used as positive controls, and 0.2% DMSO as the negative control.

(3) Unveiling conserved HIV-1 open reading frames encoding T cell antigens using ribosome profilingNat CommunFebruary 18, 2025Lisa Bertrand, Annika Nelde, Bertha Cecilia Ramirez, Isabelle Hatin, Hugo Arbes, Pauline François, Stéphane Demais, Emmanuel Labaronne, Didier Decimo, Laura Guiguettaz, et al.peptides (from HCMV, EBV, and influenza virus) were obtained from Mabtech (PepPool: CEF (CD8), human, 3616-1). 12-day in vitro T cell amplification prior to ELISPOT assay PBMCs were thawed and rested 2–3 h in

(4) T cell responses to SARS-CoV-2 infection and vaccination are elevated in B cell deficiency and reduce risk of severe COVID-19Science Translational MedicineNovember 29, 2023Reza Zonozi, Lucy C. Walters, Aaron Shulkin, Vivek Naranbhai, Pravarut Nithagon, Gabriel Sauvage, Clarety Kaeske, Katherine Cosgrove, Anusha Nathan, Rhoda Tano-Menka, et al.peptide pools at a final concentration of 1 μg/ml for 16 to 18 hours. CEF peptide pool (Mabtech Cat#3616–1; 1 μg/ml), anti-CD3 (Clone OKT3, BioLegend, 1 μg/ml; RRID: AB_11150592), and anti-CD28 antibody (Clone

(5) Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing TumorsCancer Res CommunAugust 1, 2023Francica BJ, Holtz A, Lopez J, Freund D, Chen A, Wang D, Powell D, Kipper F, Panigrahy D, Dubois RN, et al.(10–1,000 nmol/L) for 30 minutes at 37°C. After these preincubation steps, CEF peptides (catalog no. 3616-1, Mabtech) or SIINFEKL peptide (catalog no. S7951, Sigma-Aldrich) were added, and all components were

(6) A whole blood intracellular cytokine assay optimised for field site studies demonstrates polyfunctionality of CD4+ T cells in acute scrub typhusPLOS Neglected Tropical DiseasesMarch 24, 2023Manutsanun Inthawong, Nattapon Pinthong, Areerat Thaiprakhong, Tri Wangrangsimakul, Piyanate Sunyakumthorn, Jennifer Hill, Piengchan Sonthayanon, Daniel H. Paris, Susanna J. Dunachie, Barbara Kronsteinerμg/ml, positive control) and R10 (negative control). A T cell antigen control pool (CEF, Mabtech AB, 3616–1) at a final concentration of 1 μg/ml was used as a source of control antigens. Following 18 hrs of stimulation,

(7) Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contactsNature CommunicationsDecember 1, 2022Rhia Kundu, Janakan Sam Narean, Lulu Wang, Joseph Fenn, Timesh Pillay, Nieves Derqui Fernandez, Emily Conibear, Aleksandra Koycheva, Megan Davies, Mica Tolosa-Wright, et al.µg/peptide/ml), positive control pool of CMV, EBV and influenza epitopes (CEF) (1 µg/peptide/ml) (Catalogue no. 3616-1, Mabtech AB, Stockholm, Sweden) or soluble anti-CD3 and anti-CD28 (Catalogue no. FSP-0102-10, Mabtech AB

(8) Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 studyNature MedicineJune 1, 2021Jingxin Li et al.(CMV, EBV, influenza virus) HLA class I epitope peptide pool (CEF peptide pool for human CD8 T cells, 3616-1, Mabtech) as a positive control for general T cell reactivity. Bound IFN-γ was visualized using a secondary

Be the First to Write a Review!

PepPool: CEF (CD8), human from Mabtech AB

Description

Mabtech AB

Citations (8)

Reviews

PepPool: CEF (CD8), human from Mabtech AB

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map